Aventis Researchers Considering the Use of Dharmacon, Akceli Technology in RNAi Work | GenomeWeb

Researchers at the Aventis Cambridge Genomics Center are in talks to buy a broad set of siRNAs from Dharmacon and are mulling over taking a license to Akceli’s reverse transfection siRNA microarray technology to bolster their efforts to identify genes that confer sensitivity or resistance to the breast and lung cancer drug Taxotere, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.